Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALUR Allurion Technologies	$2.37 -2.1%	$2.57	$2.15 ▼ $57.25	$17.30M	-0.47	781,863 shs	49,944 shs
APYX Apyx Medical	$2.00 +17.0%	$1.39	$0.76 ▼ $2.06	$75.59M	1.21	79,615 shs	79,753 shs
INO Inovio Pharmaceuticals	$1.96 +0.5%	$1.96	$1.42 ▼ $12.33	$71.88M	1.34	629,335 shs	773,501 shs
ZYXI Zynex	$2.49 +3.3%	$2.24	$1.66 ▼ $10.62	$75.30M	0.82	165,563 shs	207,789 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALUR Allurion Technologies	0.00%	-4.82%	-20.20%	-34.09%	-91.06%
APYX Apyx Medical	0.00%	+14.29%	+20.48%	+58.73%	+47.06%
INO Inovio Pharmaceuticals	0.00%	-2.00%	-2.97%	+2.08%	-77.10%
ZYXI Zynex	0.00%	+18.57%	+8.26%	+1.63%	-72.76%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALUR Allurion Technologies	2.8732 of 5 stars	3.5	4.0	0.0	0.5	3.3	0.6
APYX Apyx Medical	2.6965 of 5 stars	0.0	5.0	4.2	3.0	1.7	0.6
INO Inovio Pharmaceuticals	3.5417 of 5 stars	3.3	2.0	4.3	2.2	0.0	0.6
ZYXI Zynex	2.0035 of 5 stars	3.2	0.0	0.0	0.0	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALUR Allurion Technologies	3.00	Buy	$22.83	863.43% Upside
APYX Apyx Medical	2.67	Moderate Buy	N/A	N/A
INO Inovio Pharmaceuticals	2.50	Moderate Buy	$9.75	397.45% Upside
ZYXI Zynex	2.33	Hold	$6.00	140.96% Upside

Current Analyst Ratings Breakdown

Latest ALUR, INO, ZYXI, and APYX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2025	INO Inovio Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$5.00 ➝ $5.00
5/14/2025	INO Inovio Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$15.00 ➝ $13.00
4/30/2025	ZYXI Zynex	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$5.00 ➝ $4.00
4/30/2025	ZYXI Zynex	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $8.00
4/15/2025	ZYXI Zynex	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform
3/27/2025	ALUR Allurion Technologies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$2.50 ➝ $2.50

(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALUR Allurion Technologies	$32.11M	0.55	N/A	N/A	($30.08) per share	-0.08
APYX Apyx Medical	$48.10M	1.57	N/A	N/A	$0.38 per share	5.26
INO Inovio Pharmaceuticals	$220K	326.70	N/A	N/A	$1.90 per share	1.03
ZYXI Zynex	$192.35M	0.39	$0.24 per share	10.20	$1.12 per share	2.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALUR Allurion Technologies	-$26.15M	-$12.50	N/A	N/A	N/A	-86.05%	N/A	-41.49%	8/12/2025 (Estimated)
APYX Apyx Medical	-$23.46M	-$0.55	N/A	N/A	N/A	-42.37%	-156.85%	-31.92%	8/6/2025 (Estimated)
INO Inovio Pharmaceuticals	-$107.25M	-$3.19	N/A	N/A	N/A	N/A	-136.93%	-89.99%	8/6/2025 (Estimated)
ZYXI Zynex	$2.99M	-$0.24	N/A	5.30	N/A	-4.30%	-23.70%	-6.23%	7/23/2025 (Estimated)

Latest ALUR, INO, ZYXI, and APYX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ALUR Allurion Technologies	-$1.53	$0.43	+$1.96	$0.20	$5.50 million	$5.58 million
5/13/2025	Q1 2025	INO Inovio Pharmaceuticals	-$0.74	-$0.51	+$0.23	-$0.51	$0.01 million	$0.07 million
5/8/2025	Q1 2025	APYX Apyx Medical	-$0.13	-$0.10	+$0.03	-$0.10	$9.39 million	$9.43 million
4/28/2025	Q1 2025	ZYXI Zynex	-$0.24	-$0.33	-$0.09	-$0.33	$30.83 million	$26.58 million
3/26/2025	Q4 2024	ALUR Allurion Technologies	-$5.00	-$7.00	-$2.00	-$7.95	$5.60 million	$5.59 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALUR Allurion Technologies	N/A	N/A	N/A	N/A	N/A
APYX Apyx Medical	N/A	N/A	N/A	N/A	N/A
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZYXI Zynex	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALUR Allurion Technologies	N/A	2.09	1.88
APYX Apyx Medical	3.21	5.45	4.64
INO Inovio Pharmaceuticals	N/A	2.63	2.63
ZYXI Zynex	2.87	3.46	2.63

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALUR Allurion Technologies	21.39%
APYX Apyx Medical	55.33%
INO Inovio Pharmaceuticals	26.79%
ZYXI Zynex	29.68%

Insider Ownership

Company	Insider Ownership
ALUR Allurion Technologies	22.40%
APYX Apyx Medical	16.80%
INO Inovio Pharmaceuticals	2.30%
ZYXI Zynex	49.28%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALUR Allurion Technologies	501	7.46 million	5.79 million	Optionable
APYX Apyx Medical	270	37.79 million	31.45 million	Optionable
INO Inovio Pharmaceuticals	320	36.67 million	35.83 million	Optionable
ZYXI Zynex	770	30.24 million	15.34 million	Optionable

ALUR, INO, ZYXI, and APYX Headlines

Recent News About These Companies

Zynex (NASDAQ:ZYXI) Stock Price Down 3.9% - What's Next?

May 30, 2025 | marketbeat.com

Here’s Why Zynex (ZYXI) Fell in Q1

May 23, 2025 | msn.com

ZYXI DEADLINE ALERT: Zynex (ZYXI) Investors Alerted to Today’s Lead Plaintiff Deadline in Securities Class Action – Hagens Berman

May 21, 2025 | morningstar.com

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zynex

May 21, 2025 | tmcnet.com

Zynex, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; May 19, 2025 ...

May 19, 2025 | gurufocus.com

Lost Money on Zynex, Inc. (ZYXI)? Contact Levi & Korsinsky Before May 19, 2025 to Join Class Action

May 19, 2025 | accessnewswire.com

Zynex, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; May 19, 2025 Deadline to file Lead Plaintiff Motion

May 19, 2025 | globenewswire.com

ZYXI Deadline: ZYXI Investors with Losses in Excess of $100K Have Opportunity to Lead Zynex, Inc. Securities Fraud Lawsuit

May 19, 2025 | prnewswire.com

ZYXI Investors Have Opportunity to Lead Zynex, Inc. ...

May 19, 2025 | gurufocus.com

ZYXI DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Zynex, Inc. ...

May 19, 2025 | gurufocus.com

ZYXI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zynex, Inc. ...

May 19, 2025 | gurufocus.com

ZYXI LAWSUIT ALERT: Levi & Korsinsky Notifies Zynex, Inc. Investors - Lead Plaintiff Deadline May 19, 2025

May 19, 2025 | accessnewswire.com

ZYXI Investors Have Opportunity to Lead Zynex, Inc. Securities Fraud Lawsuit with the Schall Law Firm

May 19, 2025 | businesswire.com

ZYXI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zynex, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

May 19, 2025 | globenewswire.com

ZYXI DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Zynex, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 19 Deadline in Securities Class Action – ZYXI

May 19, 2025 | globenewswire.com

Investors who lost money on Zynex, Inc.(ZYXI) should contact The Gross Law Firm about pending ...

May 19, 2025 | gurufocus.com

May 19, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ZYXI

May 19, 2025 | globenewswire.com

Investors who lost money on Zynex, Inc.(ZYXI) should contact The Gross Law Firm about pending Class Action - ZYXI

May 19, 2025 | prnewswire.com

Securities Lawsuit Alert: Zynex, Inc. (ZYXI) - Contact Levi & Korsinsky Before May 19, 2025

May 19, 2025 | accessnewswire.com

May 19, 2025 Deadline: Join Class Action Lawsuit Against Zynex, Inc. (ZYXI) - Contact Levi & Korsinsky

May 19, 2025 | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zynex, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZYXI

May 19, 2025 | accessnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALUR, INO, ZYXI, and APYX Company Descriptions

Allurion Technologies NYSE:ALUR

$2.37 -0.05 (-2.07%)

Closing price 06/20/2025 03:58 PM Eastern

Extended Trading

$2.36 -0.01 (-0.42%)

As of 06/20/2025 08:00 PM Eastern

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.

Apyx Medical NASDAQ:APYX

$2.00 +0.29 (+16.96%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$2.02 +0.02 (+1.25%)

As of 06/20/2025 06:01 PM Eastern

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.

Inovio Pharmaceuticals NASDAQ:INO

$1.96 +0.01 (+0.51%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.96 0.00 (-0.26%)

As of 06/20/2025 07:49 PM Eastern

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Zynex NASDAQ:ZYXI

$2.49 +0.08 (+3.32%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$2.35 -0.14 (-5.46%)

As of 06/20/2025 07:56 PM Eastern

Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time